Drugs / Peptides
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03223103 | Mar 2018 → May 2029 expected | glioblastoma | Adilia Hormigo | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01970358 | Apr 2014 → Sep 2015 | melanoma | Patrick Ott, MD, PhD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01970358 ↗ |
| Modality | Peptide | “synthetic long peptides (SLP) as vaccine substrate” NCT03223103 ↗ |